Patient Inclusion Criteria

- Age 18-65 years; - Able to provide consent to participate and having signed an Informed Consent Form (ICF); - Able and willing to comply with all study procedures; - Women of child-bearing potential agree to use medically effective contraception (oral contraception, barrier methods, spermicide, etc.) or have a partner who is sterile from enrollment to 3 months following the last injection, or have a partner who is medically unable to induce pregnancy. - Sexually active men who are considered sexually fertile must agree to use either a barrier method of contraception during the study, and agree to continue the use for at least 3 months following the last injection, or have a partner who is permanently sterile or medically unable to become pregnant; - Seropositive for dengue virus infection. - Normal screening ECG or screening ECG with no clinically significant findings; - Screening labs must be within normal limits or have only Grade 0-1 findings, except that creatinine may grade 2 at baseline; - No history of clinically significant immunosuppressive or autoimmune disease. - No history of dengue virus vaccination; no history of yellow fever vaccination - Not currently or within the previous 4 weeks taking immunosuppressive agents (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or prednisone at a dose less than 10 mg/day, or steroid equivalent).

Patient Exclusion Criteria

- Administration of an investigational compound either currently or within 30 days of first dose; - Previous receipt of an investigational product for the treatment or prevention of Zika virus infection except if subject is verified to have received placebo; - Administration of any vaccine within 4 weeks of first dose; - Administration of any monoclonal or polyclonal antibody product within 4 weeks of the first dose - Administration of any blood product within 3 months of first dose; - Pregnancy or breast feeding or have plans to become pregnant during the course of the study; - Negative serologic result for dengue virus (any serotype) or history of receipt of either dengue virus or yellow fever virus vaccination at any time in the past; - Positive serologic test for HIV, hepatitis B surface antigen (HBsAg); or any potentially communicable infectious disease as determined by the Principal Investigator or Medical Monitor; - Positive serologic test for hepatitis C (exception: successful treatment with confirmation of sustained virologic response); - Baseline evidence of kidney disease as measured by creatinine greater than 1.5 (CKD Stage II or greater); - Baseline screening lab(s) with Grade 2 or higher abnormality; - Chronic liver disease or cirrhosis; - Immunosuppressive illness including hematologic malignancy, history of solid organ or bone marrow transplantation; - Current or anticipated concomitant immunosuppressive therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or prednisone at a dose equal to or greater than 10 mg/day, or steroid equivalent); - Current or anticipated treatment with TNF-α inhibitors such as infliximab, adalimumab, etanercept; - Prior major surgery or any radiation therapy within 4 weeks of group assignment; - Any pre-excitation syndromes, e.g., Wolff-Parkinson-White syndrome; - Presence of a cardiac pacemaker or automatic implantable cardioverter defibrillator (AICD) - Metal implants within 20 cm of the planned site(s) of injection; - Presence of keloid scar formation or hypertrophic scar as a clinically significant medical condition at the planned site(s) of injection. - Prisoner or subjects who are compulsorily detained (involuntary incarceration) for treatment of either a physical or psychiatric illness; - Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements or assessment of immunologic endpoints; or - Not willing to allow storage and future use of samples for Zika virus related research - Any illness or condition that in the opinion of the investigator may affect the safety of the subject or the evaluation of any study endpoint.